Oxidative stress, inflammation and androgen receptor (AR) signaling play a pivotal role in
the initiation, development and progression of prostate cancer (PCa). Numerous papers in …

Androgen receptor (AR) signaling plays a key role not only in the initiation of prostate cancer
(PCa) but also in its transition to aggressive and invasive castration-resistant prostate cancer …

Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is
approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC) …

Background: Triple negative breast carcinomas (TNBC) do not benefit from hormonal or
Herceptin therapies. In search of novel therapeutic targets for TNBC, interest is escalating in …

Based on pioneering work by Huggins, Hodges and others, hormonal therapies have been
established as an effective approach for advanced prostate cancer (PC) for the past eight …

Hormonal cancers affect over 400,000 men and women, and contribute collectively to over
100,000 deaths in the United States alone. Thanks to advances in the understanding of …

Although initially responsive to androgen signaling inhibitors (ASIs), metastatic castration-
resistant prostate cancer (mCRPC) inevitably develops and is incurable. In addition to …

Phytoestrogens are dietary estrogens having similar structure as of estrogen. Some of these
phytoestrogens are androgen receptor (AR) antagonists and exhibit preventive role in the …

Prostate cancer (PCa) cells expressing full-length androgen receptor (AR-FL) are
susceptible to androgen deprivation therapy (ADT). However, outgrowth of castration …

Solid cancers are the most common types of cancers diagnosed globally and comprise a
large number of deaths each year. The main challenge currently in drug development for …